HomeBUSINESS
BUSINESS

GSK Poised to Re-Enter Japan Oncology Space with Novel Myeloma Drug
(Dec.6.2017)

GSK Japan President Kanako Kikuchi
A few years after offloading its oncology portfolio to Novartis in a global asset swap, GlaxoSmithKline is again turning its eyes on the cancer market, and its ambition obviously includes Japan. The company’s new Japan chief revealed on December 5 that its first target in the country will likely be multiple myeloma (MM) ...
(LOG IN FOR FULL STORY)